How much nicotinamide mononucleotide do labels and trials give?
| Product | NMN listed | Labelled schedule |
|---|---|---|
| ELITEHEALTH capsule1 | 500 mg | One capsule a day with a glass of water, or as recommended by a healthcare professional |
| Ascuoli capsule with resveratrol and Piper nigrum extract5 | 500 mg | Two capsules a day, with or without food, or as directed by a healthcare professional |
| Herodianow lozenge with resveratrol and black pepper extract6 | 500 mg | One lozenge under the tongue daily, first thing in the morning on an empty stomach, or as directed by a healthcare professional |
Strengths and label doses
The table is set at the top of the page
The authors of the Fukamizu safety trial write that in general commercially available NMN content ranges from 50 to 150 mg per capsule, as do the Yoshino trial authors.73
Doses in human trials
Repeated-dose trials gave NMN by mouth for 14 days to 24 weeks, often at 250 mg a day.248
| Trial (first author) | Dose and schedule | People | Length |
|---|---|---|---|
| Okabe2 | 125 mg twice a day (250 mg a day), or placebo | 30 healthy adults, 15 per arm | 12 weeks |
| Yoshino3 | 250 mg a day, or placebo | 13 on NMN and 12 on placebo, postmenopausal women with prediabetes who were overweight or obese | 10 weeks |
| Igarashi9 | 250 mg of NMN, or placebo | The 42 enrolled participants, healthy men aged 65 or more, 21 per group | 12 weeks |
| Kim10 | NMN (250 mg) or placebo, once a day, after waking until 12:00 or after 18:00 | 108 older adults | 12 weeks |
| Katayoshi11 | 125 mg/capsule, one capsule twice a day after meals (250 mg a day), or placebo | Thirty-six healthy men and women aged 40 to 59 | 12 weeks |
| Akasaka4 | 250 mg a day, or placebo | 14 men with diabetes aged 65 or more with reduced grip strength or walking speed | 24 weeks |
| Yi12 | Once daily: 300 mg, 600 mg or 900 mg, or placebo | 80 healthy middle-aged adults | 60 days |
| Liao13 | 300, 600 or 1200 mg a day, as powder twice daily, or placebo | 48 recreationally trained runners | 6 weeks |
| Fukamizu7 | 1250 mg once daily, or placebo | 31 healthy adults aged 20 to 65 | Up to 4 weeks |
| Pencina8 | 1 000-mg MIB-626 (an NMN formulation), or placebo | 32 overweight or obese adults aged 55 to 80 | 14 days |
When and how NMN was taken
The Kim trial, in 108 older adults over 12 weeks, gave 250 mg of NMN or placebo either after waking until 12:00 or from 18:00 until bedtime, and its authors report that only the NMN group taking it after 18:00 showed significant improvement in sleep quality.10 In the Wakabayashi crossover study of 14 healthy adult men, each took one 250 mg NMN tablet by each route: swallowed with 100 mL of water, or held under the tongue for 3 minutes.14 Every label and trial cited here gives NMN by mouth, as a tablet, capsule, lozenge or powder, and none of the labels or leaflets searched gives a water type or volume for mixing NMN powder.
Storage
The ELITEHEALTH label says to store in a cool, dry place away from excessive heat and to keep the bottle tightly closed, and gives no temperature.1 The Ascuoli label says a dry place at room temperature, and the Herodianow label says room temperature protected from heat, light and moisture.56 None of the labels searched gives storage for after mixing, and no stability data for a mixed NMN solution turned up.
Frequently asked questions
Is there an NMN cycle?
None of the three labels cited here states an on and off cycle, and every repeated-dose trial cited here dosed continuously for its stated length.
Does NMN dosage differ by age or weight in trials?
None of the trials cited here dosed by age or by body weight. The Pencina trial, in 32 overweight or obese adults aged 55 to 80 given 1 000-mg MIB-626 or placebo for 14 days, reports that changes in NMN or NAD levels were not related to sex, body mass index or age.8
What is NMN's regulatory status and is there a regulator dose?
No US drug label or approved NMN dose turned up in the DailyMed and ClinicalTrials.gov searches. The EFSA opinion describes the NMN novel food as a source of niacin up to 300 mg/day in adults, excluding pregnant and lactating women.15 The EFSA panel concludes that the novel food is safe under the proposed conditions of use for adults, excluding pregnant and lactating women.15
What safety information do labels and trials give?
The ELITEHEALTH label warns against use in pregnancy or breastfeeding.1 The Ascuoli label says it is not for use by individuals under the age of 18, and the Herodianow label tells pregnant or nursing mothers, children under 18 and individuals with a known medical condition to consult a healthcare professional first.56 The authors of the Fukamizu placebo-controlled trial, in 31 healthy adults aged 20 to 65, report 1250 mg once daily safe and well tolerated for up to 4 weeks.7 The Liao placebo-controlled trial in 48 recreationally trained runners reports no obvious adverse symptoms or abnormal ECG at 300 to 1200 mg a day for 6 weeks.13
References
- DailyMed (Mohammedjali Co.). Active ingredient. 2023. dailymed.nlm.nih.gov
- PubMed Central. Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects. 2022. pmc.ncbi.nlm.nih.gov
- PubMed Central. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. 2021. pmc.ncbi.nlm.nih.gov
- PubMed. Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind study. 2023. pubmed.ncbi.nlm.nih.gov
- DailyMed (Healgrow Inc.). Active ingredient. 2023. dailymed.nlm.nih.gov
- DailyMed (Healgrow Inc.). Active Ingredient. 2023. dailymed.nlm.nih.gov
- PubMed Central. Safety evaluation of β-nicotinamide mononucleotide oral administration in healthy adult men and women. 2022. pmc.ncbi.nlm.nih.gov
- PubMed. MIB-626, an Oral Formulation of a Microcrystalline Unique Polymorph of β-Nicotinamide Mononucleotide, Increases Circulating Nicotinamide Adenine Dinucleotide and its Metabolome in Middle-Aged and Older Adults. 2023. pubmed.ncbi.nlm.nih.gov
- PubMed Central. Chronic nicotinamide mononucleotide supplementation elevates blood nicotinamide adenine dinucleotide levels and alters muscle function in healthy older men. 2022. pmc.ncbi.nlm.nih.gov
- PubMed Central. Effect of 12-Week Intake of Nicotinamide Mononucleotide on Sleep Quality, Fatigue, and Physical Performance in Older Japanese Adults: A Randomized, Double-Blind Placebo-Controlled Study. 2022. pmc.ncbi.nlm.nih.gov
- PubMed Central. Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial. 2023. pmc.ncbi.nlm.nih.gov
- PubMed Central. The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. 2022. pmc.ncbi.nlm.nih.gov
- PubMed Central. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study. 2021. pmc.ncbi.nlm.nih.gov
- PubMed Central. Sublingual NMN administration increases early circulating terminal catabolites 2PY and 4PY compared with oral administration in healthy adult men. 2026. pmc.ncbi.nlm.nih.gov
- EFSA Journal (record). Safety of beta-nicotinamide mononucleotide (β-NMN) pursuant the regulation (EU) 2015/2283 and the bioavailability of nicotinamide from this source in the context of Directive 2002/46/EC. researchportal.lih.lu